Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.
Liyu Su, Peicheng Lin, Yi Yin et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized phase-II trial evaluated the efficacy and safety of surufatinib combined with doublet (FOLFOX/FOLFIRI) versus triplet (FOLFOXIRI) chemotherapy in patients with metastatic colorectal cancer (mCRC) who progressed after first-line treatment. The study found that surufatinib plus doublet chemotherapy achieved an objective response rate of 35.7%, while the triplet regimen had an objective response rate of 39.3% but was associated with increased toxicity and shorter overall survival.
Key findings
- In the doublet cohort, the objective response rate was 35.7% (95% CI: 18.6-55.9).
- Median progression-free survival in the doublet cohort was 5.4 months (95% CI: 3.8-7.0).
- The triplet cohort had a higher rate of grade ≥3 treatment-emergent adverse events at 71.4%.
Why it matters
The findings suggest that surufatinib combined with doublet chemotherapy may provide a viable second-line treatment option for mCRC, balancing efficacy and tolerability. Understanding the comparative effectiveness and safety profiles of these regimens is crucial for optimizing patient care.